Literature DB >> 25452116

Use of serial assessment of disease severity and liver biopsy for indication for liver transplantation in pediatric Epstein-Barr virus-induced fulminant hepatic failure.

Atsuko Nakazawa1, Natsuko Nakano, Akinari Fukuda, Seisuke Sakamoto, Ken-Ichi Imadome, Toyoichiro Kudo, Kentaro Matsuoka, Mureo Kasahara.   

Abstract

The decision to perform liver transplantation (LT) in patients with Epstein-Barr virus (EBV)-induced fulminant hepatic failure (FHF) relies on a precise assessment of laboratory and pathological findings. In this study, we analyzed clinical and laboratory data as well as the pathological features of the liver in order to evaluate the pathogenesis and the need for LT in 5 patients with EBV-induced FHF. According to the King's College criteria, the Acute Liver Failure Early Dynamic (ALFED) model, and the Japanese criteria (from the Acute Liver Failure Study Group of Japan), only 1 patient was considered to be a candidate for LT. However, explanted liver tissues in 3 cases exhibited massive hepatocellular necrosis together with diffuse CD8-positive T cell infiltration in both the portal area and the sinusoid. EBV was detected in the liver, plasma, and peripheral blood mononuclear cells (PBMNCs). In 2 cases indicated to be at moderate risk by the ALFED model, liver biopsy showed CD8-positive and EBV-encoded RNA signal-positive lymphocytic infiltration predominantly in the portal area, but massive hepatocellular necrosis was not observed. These patients were treated with immunosuppressants and etoposide under the diagnosis of EBV-induced hemophagocytic lymphohistiocytosis or systemic EBV-positive T cell lymphoproliferative disease of childhood. EBV DNA was detected at a high level in PBMNCs, although it was negative in plasma. On the basis of the pathological analysis of the explanted liver tissues, LT was proposed for the restoration of liver function and the removal of the EBV-infected lymphocytes concentrated in the liver. Detecting EBV DNA by a quantitative polymerase chain reaction in plasma and PBMNCs was informative. An accurate evaluation of the underlying pathogenesis is essential for developing a treatment strategy in patients with EBV-induced FHF.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25452116     DOI: 10.1002/lt.24052

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  2 in total

1.  Epstein-Barr Virus-Associated Acute Liver Failure Present in a 67-Year-Old Immunocompetent Female.

Authors:  Wei Zhang; Betty Chen; Yongxin Chen; Robin Chamberland; Alexa Fider-Whyte; Julia Craig; Chintalapati Varma; Alex S Befeler; Adrian M Di Bisceglie; Peter Horton; Jin-Ping Lai
Journal:  Gastroenterology Res       Date:  2016-09-20

2.  Case Report: A Case of Epstein-Barr Virus-Associated Acute Liver Failure Requiring Hematopoietic Cell Transplantation After Emergent Liver Transplantation.

Authors:  Koji Nakajima; Eitaro Hiejima; Hiroshi Nihira; Kentaro Kato; Yoshitaka Honda; Kazushi Izawa; Naoko Kawabata; Itaru Kato; Eri Ogawa; Mari Sonoda; Tatsuya Okamoto; Hideaki Okajima; Takahiro Yasumi; Junko Takita
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.